2. Search Result
Search Result
Results for "

selective binding

" in MedChemExpress (MCE) Product Catalog:

870

Inhibitors & Agonists

9

Screening Libraries

10

Fluorescent Dye

5

Biochemical Assay Reagents

60

Peptides

1

MCE Kits

12

Inhibitory Antibodies

42

Natural
Products

1

Recombinant Proteins

31

Isotope-Labeled Compounds

6

Click Chemistry

5

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15085
    MDL 105519

    		iGluR Neurological Disease
    MDL 105519 is a potent and selective antagonist of glycine binding to the NMDA receptor.
    MDL 105519
  • HY-102080
    SAFit2
    5+ Cited Publications

    		 FKBP Cancer
    SAFit2, a chemical probe, is a highly potent, highly selective FK506-binding protein 51 (FKBP51) inhibitor with a Ki of 6 nM and also enhances AKT2-AS160 binding .
    SAFit2
  • HY-117690
    dBRD9

    		PROTACs Epigenetic Reader Domain Cancer
    dBRD9,a PROTAC, can selective degrades BRD9. dBRD9 improves the bromine domain binding profile and reduces the binding activity of the whole BET family .
    dBRD9
  • HY-148739
    dBRD 9-A

    		PROTACs Epigenetic Reader Domain Cancer
    dBRD 9-A is a PROTAC which can selective degrade BRD9. dBRD 9-A improves the bromine domain binding profile and reduces the binding activity of the whole BET family .
    dBRD 9-A
  • HY-10830A
    PBPE hydrochloride

    		Estrogen Receptor/ERR Cancer
    PBPE hydrochloride is a derivative of tamoxifen (HY-13757A) and a selective ligand for the anti-estrogen binding site (AEBS), the binding affinities (Ki) of PBPE hydrochloride and MBPE to AEBS are 8.79 and 17.57 nM, respectively .
    PBPE hydrochloride
  • HY-10013
    Taranabant
    2 Publications Verification

    MK-0364

    		 Cannabinoid Receptor Metabolic Disease
    Taranabant is a highly potent and selective cannabinoid 1 (CB1) receptor inverse agonist that inhibits the binding and functional activity of various agonists, with a binding Ki of 0.13 nM for the human CB1R in vitro.
    Taranabant
  • HY-112398
    GSK1379725A

    		Epigenetic Reader Domain Others
    GSK1379725A is a selective BPTF ligand with a Kd of 2.8 uM, showing no binding activity for Brd4 .
    GSK1379725A
  • HY-107568
    Iodophenpropit dihydrobromide

    		Histamine Receptor Inflammation/Immunology
    Iodophenpropit dihydrobromide is a potent and selective histamine H3 receptor antagonist. The binding of [ 125I]Iodophenpropit is selective, saturable, readily reversible, and of high affinity (KD 0.32 nM) .
    Iodophenpropit dihydrobromide
  • HY-125627
    CP-394531

    		Glucocorticoid Receptor Androgen Receptor Neurological Disease Metabolic Disease
    CP-394531 is an efficient and highly selective non-steroidal glucocorticoid receptor (GR) antagonist, with a Ki value of 0.1 nM. CP-394531 has a weak binding to androgen receptor (AR) (Ki = 130 nM), and has almost no effect on progesterone receptor (PR) and estrogen receptors (ERα, ERβ). CP-394531 completely blocks the half-maximal agonistic effect induced by Dexamethasone (HY-14648G), with a Kif of 4.1 nM. CP-394531 can be used to study various diseases such as diabetes, obesity, depression, neurodegenerative diseases, glaucoma and Cushing's disease .
    CP-394531
  • HY-143270
    PROTAC BRD9-binding moiety 5

    		Ligands for Target Protein for PROTAC Epigenetic Reader Domain Cancer
    PROTAC BRD9-binding moiety 5 is a selective BRD9 binder with an IC50 value of 4.20 μM, can be used for the synthesis of PROTACs. PROTAC BRD9-binding moiety 5 has antiproliferative activity against cancer cells .
    PROTAC BRD9-binding moiety 5
  • HY-151927
    AChE-IN-28

    		Cholinesterase (ChE) Neurological Disease
    AChE-IN-28 (Compound 2h) is a selective slow-binding inhibitor of acetylcholinesterase with an IC50 of 0.2 nM .
    AChE-IN-28
  • HY-18628
    UMI-77
    3 Publications Verification

    		 Bcl-2 Family Cancer
    UMI-77 is a selective Mcl-1 inhibitor, which shows high binding affinity to Mcl-1 (IC50=0.31 μM). UMI-77 binds to the BH3 binding groove of Mcl-1 with Ki of 490 nM, showing selectivity over other members of anti-apoptotic Bcl-2 members.
    UMI-77
  • HY-108466
    Ro 08-2750
    4 Publications Verification

    		 Apoptosis Neurological Disease Cancer
    Ro 08-2750 is a non-peptide and reversible nerve growth factor (NGF) inhibitor which binds to NGF, and with an IC50 of ~ 1 μM. Ro 08-2750 inhibits NGF binding to p75 NTR selectively over TRKA . Ro 08-2750 is a selective MSI RNA-binding activity inhibitor, with an IC50 of 2.7 μM .
    Ro 08-2750
  • HY-136379
    CID44216842
    2 Publications Verification

    Cdc42-IN-1

    		 Ras Cancer
    CID44216842 (Cdc42-IN-1) is a potent Cdc42-selective guanine nucleotide binding lead inhibitor. The EC50s for Cdc42 WT and Cdc42Q61L mutant are 1.0 and 1.2 μM in GTP binding assay, respectively. The EC50s for Cdc42 WT and Cdc42Q61L mutant are 0.3 and 0.5 μM in GDP binding assay, respectively. Use as a molecular probe .
    CID44216842
  • HY-147057
    Rofapitide tetraxetan
    4 Publications Verification

    FAP-2286

    		 FAP Cancer
    Rofapitide tetraxetan (FAP-2286) is a potent and selective FAP-binding peptide with a mean IC50 value of 2.7 nM for binding to FAP. Rofapitide tetraxetan can be labeled with radionuclides for diagnostic applications. Rofapitide tetraxetan has antitumor activity .
    Rofapitide tetraxetan
  • HY-147057A
    Rofapitide tetraxetan acetate

    FAP-2286 acetate

    		 FAP Cancer
    Rofapitide tetraxetan (FAP-2286) acetate is a potent and selective FAP-binding peptide with a mean IC50 value of 2.7 nM for binding to FAP. Rofapitide tetraxetan acetate can be labeled with radionuclides for diagnostic applications. Rofapitide tetraxetan acetate has antitumor activity .
    Rofapitide tetraxetan acetate
  • HY-153165
    RXR antagonist 5

    		RAR/RXR Others
    RXR antagonist 5 (compound 22) is a selective retinoic acid X receptor (RXR) antagonist with binding potential to RXR evaluated by modeling.
    RXR antagonist 5
  • HY-112895
    UT-155
    2 Publications Verification

    		 Androgen Receptor Cancer
    UT-155 is a selective and potent androgen receptor (AR) antagonist, with a Ki of 267 nM for UT-155 binding to AR-LBD.
    UT-155
  • HY-100354
    C16-Ceramide
    5 Publications Verification

    		 MDM-2/p53 Apoptosis Endogenous Metabolite Cancer
    C16-Ceramide is a natural small molecule activating p53 through the direct and selective binding .
    C16-Ceramide
  • HY-P10579
    123B9
    1 Publications Verification

    		 Ephrin Receptor Cancer
    123B9, a tumor-homing agent, is a potent and selective EphA2 agonist with a Kd value of 4.0 μM. 123B9 selectively targets the EphA2 tyrosine kinase receptor ligand-binding domain. 123B9 does not appreciably inhibit the ligand binding domains of the most closely related EphA3 and EphA4 receptors .
    123B9
  • HY-138280
    DTHIB
    5 Publications Verification

    		 HSP Cancer
    DTHIB is a direct and selective heat shock factor 1 (HSF1) inhibitor with a Kd of 160 nM for DTHIB binding to the HSF1 DNA binding domain (DBD). DTHIB inhibits HSF1 cancer gene signature (HSF1 CaSig) and selectively stimulates degradation of nuclear HSF1. DTHIB has potently anticancer activities and can be used for prostate cancer research .
    DTHIB
  • HY-14319B
    Sazetidine A dihydrochloride

    		nAChR Neurological Disease
    Sazetidine A dihydrochloride is a potent ligand for the α4β2 nAChR, with high binding affinity and selectivity for this subtype. Sazetidine A dihydrochloride exhibits favorable pharmacological properties and may contribute to research targeting nicotinic receptor-related diseases. Sazetidine A dihydrochloride has been mentioned in studies investigating the binding affinity of various analogs, highlighting its importance in understanding the nAChR ligand subtype selectivity .
    Sazetidine A dihydrochloride
  • HY-23999
    BI-0115
    2 Publications Verification

    		 LOX-1 Cardiovascular Disease
    BI-0115 is a selective inhibitor of LOX-1 (IC50=5.4 μM) that blocks cellular uptake of oxLDL. BI-0115 binding triggers receptor inhibition by formation of dimers of the homodimeric ligand binding domain .
    BI-0115
  • HY-111423
    BDP8900

    		Cdc42-binding kinase Cancer
    BDP8900 is a potent and selective inhibitor of myotonic dystrophy-related Cdc42-binding kinases (MRCKα and MRCKβ). BDP8900 reduces substrate phosphorylation, leading to morphological changes, motility inhibition and invasiveness of cancer cells .
    BDP8900
  • HY-132880
    GSK251

    		PI3K Cancer
    GSK251 is a highly potent, highly selective, orally bioavailable inhibitor of PI3Kδ with a novel binding mode.
    GSK251
  • HY-12488
    LY2510924
    10+ Cited Publications

    		 CXCR Endocrinology Cancer
    LY2510924 is a potent and selective CXCR4 antagonist that blocks SDF-1 binding to CXCR4 with an IC50 of 0.079 nM.
    LY2510924
  • HY-116255
    MS453

    		Histone Methyltransferase Others
    MS453 is a potent and highly selective SETD8 inhibitor with an IC50 value of 804 nM. MS453 specifically modifies a cysteine residue close to the inhibitor binding site. MS453 is selective for 28 other methyltransferases. The crystal structure of MS453 reveals its binding mode to SETD8, providing an atomic-level view for the development of high-quality chemical probes for SETD8 .
    MS453
  • HY-12738
    PF-3882845

    		Mineralocorticoid Receptor Progesterone Receptor Cardiovascular Disease Metabolic Disease
    PF-3882845 is a remarkably high affinity selective and orally efficacious mineralocorticoid receptor (MR binding IC50=2.7 nM) antagonist for hypertension and nephropathy. PF-3882845 also binds to progesterone receptor (PR) with the binding IC50 of 310 nM .
    PF-3882845
  • HY-103358
    KF38789
    1 Publications Verification

    		 P-selectin Inflammation/Immunology
    KF38789 is a selective inhibitor of P-selectin-PSGL-1 binding. KF38789 inhibits the binding of U937 cells to immobilized P-selectin immunoglobulin G chimeric protein (P-selectin-Ig) with an IC50 value of 1.97 μM .
    KF38789
  • HY-10799
    EG00229 trifluoroacetate
    5+ Cited Publications

    		 Complement System Cancer
    EG00229 is a neuropilin 1 (NRP1) receptor antagonist. EG00229 selectively inhibits VEGF-A binding to NRP1 b1 domain with an IC50 of 3 μM, but has no effect on VEGFA binding to VEGFR-1 and VEGFR-2 .
    EG00229 trifluoroacetate
  • HY-15653
    Filorexant
    2 Publications Verification

    MK-6096

    		 Orexin Receptor (OX Receptor) Neurological Disease Endocrinology
    Filorexant (MK-6096) is an orally bioavailable potent and selective reversible antagonist of OX1 and OX2 receptor(<3 nM in binding).
    Filorexant
  • HY-110043
    (±)-Clopidogrel hydrochloride

    		P2Y Receptor Cardiovascular Disease
    (±)-Clopidogrel hydrochloride is an antithrombotic agent that is ADP-selective and orally available. (±)-Clopidogrel hydrochloride inhibits platelet aggregation by inhibiting the binding of ADP to its platelet receptors .
    (±)-Clopidogrel hydrochloride
  • HY-16582A
    Sonidegib
    5+ Cited Publications

    Erismodegib; LDE225; NVP-LDE225

    		 Smo Cancer
    Sonidegib (Erismodegib) is a potent and selective Smo antagonist with IC50 of 1.3 nM and 2.5 nM for mouse and human Smo in binding assay, respectively .
    Sonidegib
  • HY-109176
    Giredestrant
    5 Publications Verification

    GDC-9545; RG6171

    		 Estrogen Receptor/ERR Cancer
    Giredestrant (GDC-9545), a non-steroidal estrogen receptor (ER) ligand, is an orally active and selective ER antagonist. Giredestrant potently competes with Estradiol for binding and induces a conformational change within the ER ligand binding domain. Giredestrant has anti-tumor activity .
    Giredestrant
  • HY-13956S
    Pioglitazone-d4

    U 72107-d4

    		 PPAR Ferroptosis Metabolic Disease Cancer
    Pioglitazone-d4 is a deuterium labeled Pioglitazone. Pioglitazone (U 72107) is a potent and selective PPARγ agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively .
    Pioglitazone-d4
  • HY-135903
    Giredestrant tartrate

    GDC-9545 tartrate; RG6171 tartrate

    		 Estrogen Receptor/ERR Cancer
    Giredestrant tartrate (GDC-9545 tartrate), a non-steroidal ER ligand, is an orally active and selective estrogen receptor (ER) antagonist. Giredestrant tartrate potently competes with estradiol for binding and induces a conformational change within the ER ligand binding domain. Anti-tumor activity .
    Giredestrant tartrate
  • HY-164523
    PV1162

    		Checkpoint Kinase (Chk) Cancer
    PV1162 is a selective Chk2 inhibitor with an IC50 of 0.29 nM. PV1162 inhibits ATP binding to Chk2 by targeting the gatekeeper-dependent hydrophobic pocket, which is specific to Chk2 and located behind the ATP-binding site (adenine-binding region), thereby inhibiting the phosphorylation activity of Chk2. PV1162 holds potential application value in the field of cancer therapy .
    PV1162
  • HY-145817A
    lunresertib
    5 Publications Verification

    RP-6306

    		 Wee1 Cancer
    lunresertib (RP-6306) is a potent, selective and orally active PKMYT1 inhibitor with an IC50 of 14 nM. lunresertib shows a high degree of selectivity over other kinases in cellular binding assays. lunresertib shows anticancer effects .
    lunresertib
  • HY-16684
    AGN-195183

    IRX-5183; VTP-195183; NRX-195183

    		 RAR/RXR Autophagy Cancer
    AGN-195183 (IRX-5183) is a potent and selective agonist of RARα (Kd=3 nM) with improved binding selectivity relative to AGN 193836. AGN-195183 has no activity on RARβ/γ.
    AGN-195183
  • HY-P2271
    MM 54

    		Apelin Receptor (APJ) Cancer
    MM 54 (compound 5) is a competitive antagonist at APJ, with an IC50 of 93 nM. MM 54 behaves as a potent and selective inhibitor of apelin binding and APLNR activation .
    MM 54
  • HY-15676
    Idasanutlin
    45+ Cited Publications

    RG7388

    		 MDM-2/p53 E1/E2/E3 Enzyme Cancer
    Idasanutlin (RG7388) is a potent and selective MDM2 antagonist, inhibiting p53-MDM2 binding, with an IC50 of 6 nM.
    Idasanutlin
  • HY-120867
    TASP0376377

    		Prostaglandin Receptor Inflammation/Immunology
    TASP0376377 is a potent and selective CRTH2 antagonist (IC50: 13 nM). TASP0376377 has binding affinity for CRTH2 (IC50: 19 nM) .
    TASP0376377
  • HY-14319A
    Sazetidine A hydrochloride

    		nAChR Neurological Disease
    Sazetidine A hydrochloride is a potent ligand for the α4β2 nicotinic acetylcholine receptor, exhibiting high binding affinities and selectivity towards this subtype. Sazetidine A hydrochloride demonstrates promising pharmacological properties that could potentially contribute to the development of therapies targeting nicotinic receptor-related conditions. Sazetidine A hydrochloride has been implicated in studies examining the binding affinities of various analogs, highlighting its significance in understanding subtype selectivity among nAChR ligands.
    Sazetidine A hydrochloride
  • HY-110160
    Pozanicline dihydrochloride

    ABT-089 dihydrochloride

    		 nAChR Neurological Disease
    Pozanicline dihydrochloride (ABT-089 dihydrochloride) is an orally bioavailable nicotinic acetylcholine receptor (nAChR) agonist with a Ki of 16.7 nM for binding to [ 3H]cytisine sites . Pozanicline is an α4β2-selective nAChR agonist, which binds to rat brain α4β2 nAChR with a Ki of 17 nM while binding to α7 nAChR is insignificant .
    Pozanicline dihydrochloride
  • HY-13956C
    (R)-Pioglitazone

    (R)-U 72107

    		 PPAR Neurological Disease
    (R)-Pioglitazone ((+)-pioglitazone) is the R enantiomer of Pioglitazone (HY-13956). (R)-Pioglitazone is an orally active and selective peroxisome proliferator-activated receptor (PPARγ) agonist with high affinity binding to the PPARγ ligand-binding domain. (R)-Pioglitazone can be used for the research of Alzheimer's disease .
    (R)-Pioglitazone
  • HY-113734
    CM026

    		Aldehyde Dehydrogenase (ALDH) Others
    CM026 is a selective aldehyde dehydrogenase 1A1 inhibitor with submicromolar inhibitory activity against aldehyde dehydrogenase 1A1. Its inhibitory mechanism is related to binding to the aldehyde binding pocket and utilizing a unique glycine residue. It can be used as a chemical tool to study the role of this enzyme in disease.
    CM026
  • HY-15894A
    BQ-788
    5+ Cited Publications

    		 Endothelin Receptor Cardiovascular Disease Endocrinology Cancer
    BQ-788 is a potent, selective ETB receptor antagonist with IC50 of 1.2 nM for inhibition of ET-1 binding to human Girardi heart cells, poorly inhibiting the binding to ETA receptors in human neuroblastoma cell line SK-N-MC cells with IC50 of 1300 nM .
    BQ-788
  • HY-43058
    5'-O-DMT-ibu-rG

    5'-O-DMT-N2-isobutyrylguanosine

    		 Nucleoside Antimetabolite/Analog Others Cancer
    5'-O-DMT-ibu-rG is a useful model for a new class of DNA binding molecules for the development of potent and selective anti-cancer agents .
    5'-O-DMT-ibu-rG
  • HY-P6010
    αvβ6-BP

    		Integrin Cancer
    αvβ6-BP is a selective αvβ6 binding peptide, and can be used for molecular imaging .
    αvβ6-BP
  • HY-100821
    2,4-Dihydroxyphenylacetylasparagine

    		Bacterial Infection
    2,4-Dihydroxyphenylacetylasparagine is a potent and selective antagonist of glutamate. 2,4-Dihydroxyphenylacetylasparagine inhibits glutamate binding to rat brain synaptic membranes .
    2,4-Dihydroxyphenylacetylasparagine

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: